Abstract:Abstract Abstract 2689 Poster Board II-665 Introduction: Extranodal NK/T-cell lymphoma (ENKL) is a distinct clinicopathological entity of non-Hodgkin's lymphoma, which is characterized by a highly aggressive clinical process and poor prognosis. There are no standard treatment strategies available now. The present study aimed to evaluate the treatment outcome and toxicity of EPOCH regimen for ENKL. Methods: From June 2003 to June 2008, 34 patients including 30 nasal ENKL (88.2%) and 4 extranasal ENKL (11.8%) received doxorubicin, vincristine, etoposide over 96 hours infusion with bolus cyclophosphamide and oral predinisone (EPOCH) combination as first-line treatment. By the Ann Arbor lymphoma Staging Classification, 29 patients (85.3%) had stage ±E-IIE disease and 5 patients (14.7%) had stage IIIE-‡WE disease. Median cycles of EPOCH regimen administered were 2.5 (range from 1 to 6 cycles). Additional involved field radiation therapy (IFRT) was administered to patients with localized regional disease after chemotherapy. Results: Among 34 patients, 33 were eligible for objective response evaluation. The response rate (RR) for the whole group was 60.6% (20/33) with complete remission (CR) rate of 45.5% (15/33). The RR of patients with nasal ENKL was 66.7% (20/30), the CR rate was 50% (15/30). Of the 4 patients with extranasal ENKL, only one achieved stable disease (SD), the other three had progressive disease (PD) during chemotherapy. After a median follow-up of 22 (2–68) months, the estimated overall 3-year overall survival rate (OS) was 52.2%. For patients with nasal ENKL, the estimated median survival time was not reached, the 3-year OS was 59.4%. For patients with extranasal ENKL, the estimated median survival time was only 7 months. For stage ±E-IIE patients with nasal ENKL who received initial EPOCH chemotherapy followed IFRT, the CR rate was 75.0%, and the 3-year survival rate was 75.0%. 102 cycles of chemotherapy were administered to 34 patients. Major adverse effect was myelosuppression. The incidence of grade III-‡W neutropenia was 30.9% and 60 cycles needed G-CSF support. Other toxicities were mild, no treatment-related mortality occurred. Conclusion: EPOCH regiment was effective on ENKL with acceptable toxlicity. EPOCH followed by IFRT yielded promising outcome for patients with localized nasal ENKL. However, patients with extranasal ENKL responded poorly, and more efficacious treatment strategies are urgently needed. Disclosures: No relevant conflicts of interest to declare.

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Stage IE/IIE Extranodal Natural Killer/t Cell Lymphoma, Nasal Type: 13-Year Follow-Up in 135 Patients.

Long-Term Outcomes Of Patients With Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma Treated By Etoposide, Prednisone, Vincristine, Cyclophosphamide, And Doxorubicin Regimen: A Single-Institution Experience

Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I E /II E extranodal natural killer/T-cell lymphoma.

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

Long-Term Efficacy of Sequential Dice Chemotherapy with Regional Field Radiation Therapy for Stages I-Ii Natural Killer/T-Cell Lymphoma, Nasal Type: Analysis of 118 Cases

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity.

Long-Term Outcomes of Patients with Newly Diagnosed Nk/T-Cell Lymphoma Treated by Epoch Regimen

Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.

The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study

Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma

[Effectiveness of P-Gemox Chemotherapy Combined with Radiotherapy in Newly Diagnosed,stage ⅠE to ⅡE, Extranodal Nasal Type Natural Killer/t-Cell Lymphoma].

Clinical Characteristics and Treatment of 69 Patients with Extranodal Natural Killer T-cell Lymphoma

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.

Radiation Therapy Alone Not Inferior to Chemoradiation in the Patients with Stage I Nasal Natural Killer/T-Cell Lymphoma

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Chemotherapy with Sandwiched Radiotherapy in the Treatment of Newly Diagnosed Stage IE/IIE Extranodal Natural Killer/t‐cell Lymphoma, Nasal Type

Phase II/III Randomized Trial of CID-ATT with Radiotherapy Compared with CHOP with Radiotherapy As First-Line Treatment for Previously Untreated Early Staging Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL).

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed by Extensive Involved-Field Radiotherapy(Eifrt) for Newly Diagnosed Stage I/Ii Extranodal Natural Killer/T-Cell Lymphoma-A Single Center Experience

A Phase Ii Prospective Study of the "sandwich" Protocol, L-Asparaginase, Cisplatin, Dexamethasone and Etoposide Chemotherapy Combined with Concurrent Radiation and Cisplatin, in Newly Diagnosed, I/Ii Stage, Nasal Type, Extranodal Natural Killer/T-Cell Lymphoma

Treatment outcome and prognosis of patients with stage Ⅰ—Ⅱ nasal-type natural killer/T-cell lymphoma receiving induction chemotherapy with GELOX regimen and radical radiotherapy